Beam's Risto-cel Clears Pivotal Sickle Cell Trial, BLA Filing Set for Year-End
BEAM sits 35% above its 52-week low of $20.23.
Summary
Beam's BEACON Phase 1/2 trial of risto-cel hit both its primary efficacy and safety endpoints in sickle cell disease, and every secondary endpoint including freedom from hospitalization for vaso-occlusive crises. The single-arm trial in SCD patients with severe vaso-occlusive crises measured its primary efficacy endpoint as freedom from severe VOCs for at least 12 consecutive months, on a data cut date of Oct. 20, and full BEACON results will be disclosed at a medical meeting next year. That is the full package a gene-editing program needs before filing, and Beam says it will submit a BLA to the FDA by year-end 2026. This is the most important clinical readout in the company's history and lands on a $2.8B market cap stock trading at $27.40, though shares fell more than 10% Tuesday despite the positive readout; UBS reiterated Hold with a $28 target, noting investor focus remains on the AATD program. It also comes after a rough stretch: shares fell 9% in September on disappointing BEAM-302 AATD data, and the Q3 report on November 3 showed a $134.4M loss with $1.0B in cash. The cash covers the filing and launch prep, so the BLA submission by year-end is the next hard checkpoint.
Updated with a Seeking Alpha report · What changed
Updates
· Seeking Alpha — Beam shares fell more than 10% Tuesday despite the positive BEACON readout; UBS reiterated Hold with a $28 target, noting investor focus remains on the AATD program.
- Trial Design — The trial was a single-arm study in SCD patients with severe vaso-occlusive crises.
- Primary Endpoint — The primary efficacy endpoint was freedom from severe VOCs for at least 12 consecutive months, on a data cut date of Oct. 20.
- Results Disclosure — Full BEACON results are planned to be disclosed at a medical meeting next year.
All 4 details
- Primary efficacy endpoint: freedom from severe VOCs for at least 12 consecutive months
- Data cut date: Oct. 20
- Single-arm trial in SCD patients with severe vaso-occlusive crises
- Full BEACON results to be disclosed at a medical meeting next year
At the time of this announcement, BEAM was trading at $27.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.8B. The 52-week trading range was $20.23 to $38.26. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.